People who tested positive for COVID-19 and took ivermectin as a treatment recovered faster than a comparison group, a new study found.
The time to self-reported recovery was a median of two days faster among the ivermectin recipients, according to the large UK study.
People who received ivermectin were also less likely to be hospitalized or die, with 1.6 percent of ivermectin recipients being hospitalized or dying versus 4 percent of the comparison group, which received typical care, which in the UK is largely focused on managing symptoms.
The study covered an open-label trial that involved 2,157 ivermectin recipients and 3,256 who received typical care from June 23, 2021, to July 1, 2022.
"Ivermectin is readily available globally, has been in wide use for many other infectious conditions so it's a well-known medicine with a good safety profile, and because of the early promising results in some studies it is already being widely used to treat COVID-19 in several countries," Dr. Christopher Butler, a University of Oxford professor and joint chief investigator of the trial, said when it was announced ivermectin would be assessed.
"By including ivermectin in a large-scale trial like PRINCIPLE, we hope to generate robust evidence to determine how effective the treatment is against COVID-19, and whether there are benefits or harms associated with its use." Doctors Weigh In Dr. Pierre Kory, an American physician who was not involved in the trial, said that the authors wrongly downplayed how ivermectin improved recovery from COVID-19.
Ivermectin works best when applied within 24 hours of symptom manifestation, according to a meta-regression of ivermectin studies.
No comments:
Post a Comment